Full-Time

Document Specialist

Confirmed live in the last 24 hours

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Biotechnology
Healthcare

Compensation Overview

$115k - $124kAnnually

+ Equity Component + Comprehensive Benefits

Junior, Mid

San Carlos, CA, USA

Hybrid position.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Visio
PowerPoint/Keynote/Slides
Requirements
  • Bachelor’s BA/BS degree or equivalent experience.
  • 2+ years of biopharmaceutical industry experience.
  • Experience with managing key Quality Management System processes (e.g., Document Control, Change Management, Training).
  • 2+ years of experience with document management utilizing EDMS systems, Experience with Veeva QualityDocs preferred.
  • Familiarity with documents and records associated with GxP manufacturing and testing activities.
  • Understanding of current regulatory expectations including 21CFR Part 11 requirements.
  • Demonstrated ability to collaborate and influence across organization to gain support and commitment for team goals; effective management of groups of professionals to achieve desired results.
  • Strong professional interpersonal and communications skills, both verbal and written, to provide clear direction for the business, vendors, and internal stakeholders.
  • Strong attention to detail, organizational skills, ability to work in a faced paced environment.
  • Ability to meet deadlines and multi-task efficiently.
  • Working knowledge with SmartSheet, Microsoft Office Suite, Word, Excel, PowerPoint, Visio, and Adobe.
Responsibilities
  • Maintenance of the Quality Systems documentation in Veeva (electronic document control system) and other electronic systems where required.
  • Perform document specialist functions in QA, including managing the lifecycle of GMP documents in Veeva, including creation, revision, approval, distribution and archival, ensuring compliance with internal procedures and regulatory standards.
  • Work closely with quality assurance, external vendors, functional areas and Project Management team for daily management of routing, revisions, approval, and filing of documents within defined timelines.
  • Organize and ensure accurate and reliable filing systems for all electronic and paper-based GMP documents.
  • Support audits as appropriate (internal and regulatory).

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA for adult use. Vaxcyte employs advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while eliciting a strong immune response. Unlike traditional cell-based methods, their approach allows for the development of broad-spectrum vaccines. Vaxcyte's goal is to provide effective vaccines that can significantly reduce the impact of bacterial infections on global health.

Company Stage

IPO

Total Funding

$273.3M

Headquarters

Foster City, California

Founded

2013

Growth & Insights
Headcount

6 month growth

23%

1 year growth

61%

2 year growth

132%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments from major financial entities like Vanguard and Mutual of America Capital Management indicate strong market confidence in Vaxcyte's potential.
  • The recent $816.5 million raised through stock and warrant sales provides substantial capital for advancing their vaccine pipeline.
  • The appointment of experienced board members like John Furey can provide strategic guidance and enhance corporate governance.

What critics are saying

  • The success of Vaxcyte heavily depends on the clinical and commercial success of its lead product, VAX-24, which is still subject to regulatory approval.
  • The competitive landscape in vaccine development is intense, with numerous established players potentially overshadowing Vaxcyte's market entry.

What makes Vaxcyte unique

  • Vaxcyte leverages its proprietary XpressCF™ cell-free protein synthesis platform, which allows for more efficient and versatile vaccine production compared to traditional cell-based methods.
  • Their focus on broad-spectrum vaccines, such as VAX-24 targeting 24 strains of Streptococcus pneumoniae, sets them apart in the vaccine development landscape.
  • The FDA Breakthrough Therapy designation for VAX-24 underscores the innovative potential and clinical significance of their lead product.

Help us improve and share your feedback! Did you find this helpful?